Neoadjuvant nivolumab for patients with non-metastatic high risk kidney cancer

A recent phase 1 trial showed that treatment with nivolumab before surgery (neoadjuvant treatment) was tolerable in patients with high-risk clear cell renal cell carcinoma (RCC) that had not spread. These results were presented at the 21st Annual Meeting of the Society of Urologic Oncology (SUO). The study was a phase 1 trial that looked […]

read more

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

A recent retrospective study (looking back at the patients’ cases after treatment had occurred) has shown that patients with metastatic renal cell carcinoma (RCC) who were treated with targeted therapy, such as sunitinib or pazopanib, or immunotherapy, such as nivolumab, had better survival outcomes if went on to have surgery to remove the kidney. This […]

read more

Nephrectomy after complete response to immunotherapy

A retrospective study looked at the clinical and surgical outcomes in 11 patients with metastatic clear cell renal cell carcinoma (RCC) who had a delayed nephrectomy following a complete response to immunotherapy or immunotherapy and targeted therapy combinations. There were surgical difficulties in 81.8% of cases caused by adhesions and inflammatory reactions. At 15 months […]

read more

ESMO 2019: ADAPTeR study to evaluate the role of nivolumab before and after surgery – results of biomarker analysis

Results from the ADAPTeR study to evaluate the role of anti-PD1 checkpoint inhibitors before and after surgery in patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. ADAPTeR is a single centre study in which metastatic RCC patients were treated with […]

read more

ESMO 2019: Avelumab plus axitinib in patients who had not had nephrectomy

Results from a post-hoc analysis of JAVELIN-Renal 101 in patients with advanced renal cell carcinoma (RCC) who had not had a prior nephrectomy were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. The JAVELIN Renal 101 study demonstrated a significant improvement in progression-free survival with avelumab plus axitinib […]

read more

Neoadjuvant axitinib to allow partial nephrectomy of cT2a renal tumours

A phase 2 study published in the British Journal of Urology last year evaluated the effectiveness of neoadjuvant axitinib given before surgery to reduce the size of renal tumours (stage cT2a) to enable partial nephrectomy in 18 patients. The tumours decreased in size in 16 of the 18 patients, and these 16 patients had a […]

read more

Kidney cancer experts talk about the latest advances in treatments

The following interviews with kidney cancer experts discuss the latest advances in the treatment of renal cell carcinoma (RCC) and renal masses: No OS signal in axitinib + avelumab combination therapy – Dr Toni Choueiri, Dana Faber Cancer Institute, Boston, USA Treating renal masses with minimal invasive ablative technique – Dr Alessandro Volpe, Maggiore Della […]

read more

EAU 2019

The European Association of Urology (EAU) held its annual congress in Barcelona, Spain this month. There were presentations about partial nephrectomy, neoadjuvant treatment of renal cell carcinoma (RCC), and the management of RCC. Here are some of the more interesting RCC presentations for you to browse through: EAU 2019: The Challenging Landscape in Advanced Renal […]

read more

Neoadjuvant axitinib shrinks kidney tumours to allow for partial nephrectomy

A recent phase II study of 18 patients with clear-cell renal cell carcinoma (RCC) stage cT2a showed that treatment with axitinib before surgery (neoadjuvant treatment) reduced the size of the tumour. Before treatment with axtinib, these patients were not considered suitable for partial nephrectomy. Neoadjuvant treatment with axitinib enabled 67% of patients to undergo partial nephrectomy […]

read more

Adjuvant therapy for renal cell carcinoma

The following articles from various urology conferences in 2018 summarise the status of research with respect to adjuvant therapy after nephrectomy for people with localised renal cell carcinoma (RCC). Many adjuvant therapies have been assessed in clinical trials, such as radiotherapy, vaccines, immunotherapy, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI), and checkpoint inhibitors. […]

read more
Showing 1 to 10 of 15 results
  TOP